Literature DB >> 22270368

Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor.

Takumi Kawabata1, Susumu Tanimura, Kohei Asai, Ryohei Kawasaki, Yumi Matsumaru, Michiaki Kohno.   

Abstract

Blockade of the ERK signaling pathway by ERK kinase (MEK) inhibitors selectively enhances the induction of apoptosis by microtubule inhibitors in tumor cells in which this pathway is constitutively activated. We examined the mechanism by which such drug combinations induce enhanced cell death by applying time-lapse microscopy to track the fate of individual cells. MEK inhibitors did not affect the first mitosis after drug exposure, but most cells remained arrested in interphase without entering a second mitosis. Low concentrations of microtubule inhibitors induced prolonged mitotic arrest followed by exit of cells from mitosis without division, with most cells remaining viable. However, the combination of a MEK inhibitor and a microtubule inhibitor induced massive cell death during prolonged mitosis. Impairment of spindle assembly checkpoint function by RNAi-mediated depletion of Mad2 or BubR1 markedly suppressed such prolonged mitotic arrest and cell death. The cell death was accompanied by up-regulation of the pro-apoptotic protein Bim (to which MEK inhibitors contributed) and by down-regulation of the anti-apoptotic protein Mcl-1 (to which microtubule and MEK inhibitors contributed synergistically). Whereas RNAi-mediated knockdown of Bim suppressed cell death, stabilization of Mcl-1 by RNAi-mediated depletion of Mule slowed its onset. Depletion of Mcl-1 sensitized tumor cells to MEK inhibitor-induced cell death, an effect that was antagonized by knockdown of Bim. The combination of MEK and microtubule inhibitors thus targets Bim and Mcl-1 in a cooperative manner to induce massive cell death in tumor cells with aberrant ERK pathway activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22270368      PMCID: PMC3322996          DOI: 10.1074/jbc.M111.319426

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

Review 1.  Unwinding the loop of Bcl-2 phosphorylation.

Authors:  M V Blagosklonny
Journal:  Leukemia       Date:  2001-06       Impact factor: 11.528

2.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation.

Authors:  Deepak Nijhawan; Min Fang; Elie Traer; Qing Zhong; Wenhua Gao; Fenghe Du; Xiaodong Wang
Journal:  Genes Dev       Date:  2003-06-03       Impact factor: 11.361

3.  Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44.

Authors:  Susumu Tanimura; Keita Asato; Shuh-hei Fujishiro; Michiaki Kohno
Journal:  Biochem Biophys Res Commun       Date:  2003-05-16       Impact factor: 3.575

Review 4.  Targeting the extracellular signal-regulated kinase pathway in cancer therapy.

Authors:  Michiaki Kohno; Susumu Tanimura; Kei-ichi Ozaki
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

Review 5.  Histone H3 phosphorylation and cell division.

Authors:  F Hans; S Dimitrov
Journal:  Oncogene       Date:  2001-05-28       Impact factor: 9.867

6.  MEK inhibition enhances paclitaxel-induced tumor apoptosis.

Authors:  J P MacKeigan; T S Collins; J P Ting
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

7.  Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.

Authors:  Frederic Luciano; Arnaud Jacquel; Pascal Colosetti; Magali Herrant; Sebastien Cagnol; Gilles Pages; Patrick Auberger
Journal:  Oncogene       Date:  2003-10-02       Impact factor: 9.867

8.  MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol.

Authors:  Aaron M Domina; Julie A Vrana; Mark A Gregory; Stephen R Hann; Ruth W Craig
Journal:  Oncogene       Date:  2004-07-08       Impact factor: 9.867

9.  DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells.

Authors:  Andrea Cuconati; Chandreyee Mukherjee; Denise Perez; Eileen White
Journal:  Genes Dev       Date:  2003-11-21       Impact factor: 11.361

Review 10.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

View more
  12 in total

1.  Muscle Segment Homeobox Genes Direct Embryonic Diapause by Limiting Inflammation in the Uterus.

Authors:  Jeeyeon Cha; Kristin E Burnum-Johnson; Amanda Bartos; Yingju Li; Erin S Baker; Susan C Tilton; Bobbie-Jo M Webb-Robertson; Paul D Piehowski; Matthew E Monroe; Anil G Jegga; Shigeo Murata; Yasushi Hirota; Sudhansu K Dey
Journal:  J Biol Chem       Date:  2015-04-30       Impact factor: 5.157

2.  The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.

Authors:  Aziz Zaanan; Koichi Okamoto; Hisato Kawakami; Khashayarsha Khazaie; Shengbing Huang; Frank A Sinicrope
Journal:  J Biol Chem       Date:  2015-08-05       Impact factor: 5.157

3.  Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor.

Authors:  Lili Han; Peiling Wang; Yang Sun; Sijing Liu; Jun Dai
Journal:  J Cancer       Date:  2017-08-25       Impact factor: 4.207

4.  Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.

Authors:  Xin-Yan Pei; Yun Dai; Jessica Felthousen; Shuang Chen; Yukie Takabatake; Liang Zhou; Leena E Youssefian; Michael W Sanderson; Wesley W Bodie; Lora B Kramer; Robert Z Orlowski; Steven Grant
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

5.  Mcl-1 dynamics influence mitotic slippage and death in mitosis.

Authors:  Olivia Sloss; Caroline Topham; Maria Diez; Stephen Taylor
Journal:  Oncotarget       Date:  2016-02-02

Review 6.  Targeting the Mitotic Catastrophe Signaling Pathway in Cancer.

Authors:  Margaret M Mc Gee
Journal:  Mediators Inflamm       Date:  2015-09-27       Impact factor: 4.711

7.  All-Trans Retinoic Acid Induces Proliferation, Survival, and Migration in A549 Lung Cancer Cells by Activating the ERK Signaling Pathway through a Transcription-Independent Mechanism.

Authors:  Reyna Sara Quintero Barceinas; Alejandro García-Regalado; Elena Aréchaga-Ocampo; Nicolás Villegas-Sepúlveda; Claudia Haydée González-De la Rosa
Journal:  Biomed Res Int       Date:  2015-10-18       Impact factor: 3.411

8.  Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers.

Authors:  Ailsa Bennett; Olivia Sloss; Caroline Topham; Louisa Nelson; Anthony Tighe; Stephen S Taylor
Journal:  Open Biol       Date:  2016-08       Impact factor: 6.411

9.  In vitro transfection of anti-tumor miR-101 induces BIM, a pro-apoptotic protein, expression in acute myeloid leukemia (AML).

Authors:  Narges Nikoonahad Lotfabadi; Homa Mohseni Kouchesfahani; Mohammad Hasan Sheikhha; Seyed Mehdi Kalantar
Journal:  EXCLI J       Date:  2017-11-27       Impact factor: 4.068

Review 10.  Perturbing mitosis for anti-cancer therapy: is cell death the only answer?

Authors:  Manuel Haschka; Gerlinde Karbon; Luca L Fava; Andreas Villunger
Journal:  EMBO Rep       Date:  2018-02-19       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.